Author Title Type [ Year(Asc)]
Filters: Author is Ganser, Arnold  [Clear All Filters]
Seitz, A., Wollert, K.C., Meyer, G.P., Müller-Ehmsen, J., Tschöpe, C., May, A.E., Empen, K., Chorianopoulos, E., Ritter, B., Pirr, J., et al. (2019). Adenosine stress perfusion cardiac magnetic resonance imaging in patients undergoing intracoronary bone marrow cell transfer after ST-elevation myocardial infarction: the BOOST-2 perfusion substudy.Clin Res Cardiol.
Shimoni, A., Labopin, M., Savani, B., Byrne, M., Volin, L., Finke, J., Niederwieser, D., Ehninger, G., Blaise, D., Beelen, D., et al. (2019). Comparable Long-Term Outcome after Allogeneic Stem-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT.Biol Blood Marrow Transplant.
Varanasi, P.Reddy, Ogonek, J., Luther, S., Dammann, E., Stadler, M., Ganser, A., Borchers, S., Hambach, L., and Weissinger, E.M. (2019). Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation.Plos One14, e0213739.
Schlenk, R.F., Paschka, P., Krzykalla, J., Weber, D., Kapp-Schwoerer, S., Gaidzik, V.I., Leis, C., Fiedler, W., Kindler, T., Schroeder, T., et al. (2019). Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.J Clin OncolJCO1901406.
Chaturvedi, A., Goparaju, R., Gupta, C., Weder, J., Klünemann, T., Cruz, M.Maria Arau, Kloos, A., Goerlich, K., Schottmann, R., Othman, B., et al. (2019). In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.Leukemia.
Jyotsana, N., Sharma, A., Chaturvedi, A., Budida, R., Scherr, M., Kuchenbauer, F., Lindner, R., Noyan, F., Sühs, K.-W., Stangel, M., et al. (2019). Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.Ann Hematol.
Bialek-Waldmann, J.K., Heuser, M., Ganser, A., and Stripecke, R. (2019). Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation.Cancer Immunol Immunother.
Ringdén, O., Boumendil, A., Labopin, M., Canaani, J., Beelen, D., Ehninger, G., Niederwieser, D., Finke, J., Stelljes, M., Gerbitz, A., et al. (2019). OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT.Biol Blood Marrow Transplant.
Schoenherr, C., Wohlan, K., Dallmann, I., Pich, A., Hegermann, J., Ganser, A., Hilfiker-Kleiner, D., Heidenreich, O., Scherr, M., and Eder, M. (2019). Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase.Plos One14, e0225977.